Cited by 115Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on BehaviorAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin

Open access

Mason, Barbara J., Light, John M., Williams, Lauren D., Drobes, David J.·2009·Addiction Biology

DOI 10.1111/j.1369-1600.2008.00133.xPMC PMC2758315

Open this paper in CoChat — free account

Abstract

There is a need for safe medications that can effectively support recovery by treating symptoms of protracted abstinence that may precipitate relapse in alcoholics, e.g. craving and disturbances in sleep and mood. This proof‐of‐concept study reports on the effectiveness of gabapentin 1200 mg for attenuating these symptoms in a non‐treatment‐seeking sample of cue‐reactive, alcohol‐dependent individuals. Subjects were 33 paid volunteers with current Diagnostic and Statistical Manual of Mental Disorders‐IV alcohol dependence and a strength of craving rating 1 SD or greater for alcohol than water cues. Subjects were randomly assigned to gabapentin or placebo for 1 week and then participated in a within‐subjects trial where each was exposed to standardized sets of pleasant, neutral and unpleasant visual stimuli followed by alcohol or water cues. Gabapentin was associated with significantly greater reductions than placebo on several measures of subjective craving for alcohol as well as for affectively evoked craving. Gabapentin was also associated with significant improvement on several measures of sleep quality. Side effects were minimal, and gabapentin effects were not found to resemble any major classes of abused drugs. Results suggest that gabapentin may be effective for treating the protracted abstinence phase in alcohol dependence and that a randomized clinical trial would be an appropriate next step. The study also suggests the value of cue‐reactivity studies as proof‐of‐concept screens for potential antirelapse drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1369-1600.2008.00133.x

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Measuring emotion: The self-assessment manikin and the semantic differential
Bradley, M. M., & Lang, P. J. (1994) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/0005-7916(94)90063-9 · Cited by 9,538
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Drug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535
Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar)
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988

Show all 63 references

Research works printed but not linked: 8

Baker TB, 1987, In, 257
Cook EW, 1987, Stimulus control and data acquisition for IBM PCs and compatibles, Psychophysiology, 24, 726
First MB, 1996, Structured Clinical Interview for DSM‐IV Axis I Disorders—Patient Edition (SCID‐I/P, Version 2.0)
HargensL(2008)Interpreting product—variable models of interaction effects.Soc Sci Res. (In press).
Marlatt GA, 1985, Relapse Prevention, 71
Rasbash J, 2000, A User's Guide to MLwiN
Singleton EG, 1994, Alcohol Craving Questionnaire: ACQ‐Now: Background and Administration Manual
Skinner H, 1984, Alcohol Dependence Scale: User's Guide

Sorted by citations

Advances in the science and treatment of alcohol use disorder
Witkiewitz, K. A., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 629
Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review
Angarita, G. A., Emadi, N., Hodges, S. E., & MORGAN, P. T. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0056-7 · Cited by 376
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340
Self-citation
A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.14 · Cited by 242
Self-citation
Alcohol Dependence and Its Relationship With Insomnia and Other Sleep Disorders
Chakravorty, S., Chaudhary, N. S., & Brower, K. J. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13217 · Cited by 262
Glutamatergic medications for the treatment of drug and behavioral addictions
Olive, M. F., Cleva, R. M., Kalivas, P. W., & Malcolm, R. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.015 · Cited by 211
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19
Koob, G. F., Powell, P., & White, A. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20091375 · Cited by 166
The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study
Kwako, L. E., Spagnolo, P. A., Schwandt, M. L., Thorsell, A., George, D. T., Momenan, R., Rio, D. E., Huestis, M. A., Anizan, S., Concheiro, M., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.306 · Cited by 160
Development of pharmacotherapies for drug addiction: a Rosetta stone approach
Koob, G. F., Kenneth Lloyd, G., & Mason, B. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2828 · Cited by 154
Self-citation
Gabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence
Anton, R. F., Myrick, H., Wright, T. M., Latham, P. K., Baros, A. M., Waid, L. R., & Randall, P. K. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10101436 · Cited by 157
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Brezing, C., & LEVIN, F. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.212 · Cited by 148
Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation
Arab, J. P., Izzy, M. J., Leggio, L., Bataller, R. A., & Shah, V. H. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00527-0 · Cited by 129
Existing and future drugs for the treatment of the dark side of addiction
Koob, G. F., & Mason, B. J. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103143 · Cited by 121
Self-citation
Operant Behavior and Alcohol Levels in Blood and Brain of Alcohol‐Dependent Rats
Gilpin, N. W., Smith, A. D., Cole, M., Weiss, F., Koob, G. F., & Richardson, H. N. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01051.x · Cited by 122
Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals
Higley, A. E., Crane, N. A., Spadoni, A. D., Quello, S. B., Goodell, V., & Mason, B. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2355-8 · Cited by 116
Self-citation
Alcohol Use Disorder Treatment: Problems and Solutions
Koob, G. F. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031323-115847 · Cited by 126
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
Self-citation
Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety
Litten, R. Z., Wilford, B. B., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Substance Abuse · doi:10.1080/08897077.2015.1133472 · Cited by 94
Pharmacotherapy for Alcohol Use Disorder
Swift, R. M., & Aston, E. R. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000079 · Cited by 97
Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety
Falk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13917 · Cited by 89
Self-citation
Pharmacological approaches to reducing craving in patients with alcohol use disorders
Haass-Koffler, C. L., Leggio, L., & Kenna, G. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0149-3 · Cited by 83
Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation
Addolorato, G., Leggio, L., Hopf, F. W., Diana, M., & Bonci, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.216 · Cited by 86
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review
Ahmed, S., Bachu, R., Kotapati, V. P., Adnan, M., Ahmed, R., Farooq, U., Saeed, H., Khan, A., Zubair, A. S., Qamar, I., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00228 · Cited by 80
New horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 75
Translational opportunities in animal and human models to study alcohol use disorder
Nieto, S. J., Grodin, E. N., Aguirre, C. G., Izquierdo, A., & Ray, L. A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01615-0 · Cited by 69
Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
McAnally, H. B., Bonnet, U., & Kaye, A. D. (2020) · Pain and Therapy · doi:10.1007/s40122-020-00189-x · Cited by 63
Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 62
Gabapentin Therapy in Psychiatric Disorders
Berlin, R. K., Butler, P. M., & Perloff, M. D. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01821 · Cited by 64
Acute Intravenous Synaptamine Complex Variant KB220™ “Normalizes” Neurological Dysregulation in Patients during Protracted Abstinence from Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports
Miller, D. K., Bowirrat, A., Manka, M., Miller, M., Stokes, S., Manka, D., Allen, C., Gant, C. E., Downs, B. W., Smolen, A., et al. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2236 · Cited by 57
Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
Copeland, J., & Pokorski, I. (2016) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s89857 · Cited by 59
Human Laboratory Paradigms in Alcohol Research
Plebani, J. G., Ray, L. A., Morean, M. E., Corbin, W. R., MacKillop, J. M., Amlung, M. T., & King, A. C. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01704.x · Cited by 58
Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment
Clapp, P., Wackernah, R. C., & Minnick, M. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37907 · Cited by 58
Alcohol use disorder in community management of chronic liver diseases
Leggio, L., & Mellinger, J. L. (2022) · Hepatology · doi:10.1002/hep.32531 · Cited by 51
Genetically Selected Alcohol Preferring Rats to Model Human Alcoholism
Ciccocioppo, R. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_199 · Cited by 49
Neurobiology of Craving: Current Findings and New Directions
Ray, L. A., & Roche, D. J. O. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0202-2 · Cited by 54
Medications Acting on the GABA System in the Treatment of Alcoholic Patients
Caputo, F., & Bernardi, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516468 · Cited by 47
Emerging pharmacotherapies for alcohol use disorder
Mason, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.032 · Cited by 47
Self-citation
Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence
Ray, L. A., Hutchison, K. E., & Tartter, M. A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516422 · Cited by 46
Laboratory-induced stress and craving among individuals with prescription opioid dependence
Back, S. E., Grös, D. F., Price, M., LaRowe, S. D., Flanagan, J. C., Brady, K. T., Davis, C., Jaconis, M., & McCauley, J. L. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.019 · Cited by 46
The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
Pomrenze, M. B., Fetterly, T. L., Winder, D. G., & Messing, R. O. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13507 · Cited by 46
Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm
Bujarski, S., Jentsch, D., Roche, D. J. O., Ramchandani, V. A., Miotto, K. A., & Ray, L. A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0086-9 · Cited by 42
Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat
de Guglielmo, G., Cippitelli, A., Somaini, L., Gerra, G., Li, H., Stopponi, S., Ubaldi, M., Kallupi, M., & Ciccocioppo, R. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00468.x · Cited by 39
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Miranda, R., O’Malley, S. S., Padovano, H. T., Wu, R., Falk, D. E., Ryan, M. L., Fertig, J. B., Chun, T. H., Muvvala, S. B., & Litten, R. Z. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14352 · Cited by 37
Experimental Psychiatric Illness and Drug Abuse Models: From Human to Animal, an Overview
Edwards, S., & Koob, G. F. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-458-2_2 · Cited by 37
Experimental medicine in drug addiction: towards behavioral, cognitive and neurobiological biomarkers
Duka, T., Crombag, H. S., & Stephens, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110388324 · Cited by 37
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics
Schacht, J. P., Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2996-x · Cited by 36
Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis
Cheng, Y., Huang, Y., & Huang, W. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2751 · Cited by 34
Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research
Bujarski, S., & Ray, L. A. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.05.008 · Cited by 37
Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
Leggio, L., Falk, D. E., Ryan, M. L., Fertig, J. B., & Litten, R. Z. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_295 · Cited by 32
An approach to the patient with substance use and abuse.
Maldonado, J. (2010) · The Medical clinics of North America · doi:10.1016/j.mcna.2010.08.010 · Cited by 31
Evidence-based Treatment Options in Cannabis Dependency
Walther, L., Gantner, A., Heinz, A., & Majiić, T. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0653 · Cited by 30
Crosstalk between Sleep Disturbance and Opioid Use Disorder: A Narrative Review.
Fathi, H. R., Yoonessi, A., Khatibi, A., Rezaeitalab, F., & Ardanı, A. R. (2020) · PubMed Central · doi:10.22122/ahj.v12i2.249 · Cited by 30
Leitlinienorientierte Behandlung alkoholbezogener Störungen
Mann, K. F., Hoch, E., Batra, A., Bonnet, U., Günthner, A., Reymann, G., Soyka, M., Wodarz, N., & Schäfer, M. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-0022-8 · Cited by 29
Mobile alcohol biosensors and pharmacotherapy development research
Roberts, W., & McKee, S. A. (2018) · Alcohol · doi:10.1016/j.alcohol.2018.07.012 · Cited by 31
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29
Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat
Stopponi, S., Somaini, L., Cippitelli, A., de Guglielmo, G., Kallupi, M., Cannella, N., Gerra, G., Massi, M., & Ciccocioppo, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2457-3 · Cited by 27
2 -1 Signaling in Nucleus Accumbens Is Necessary for Cocaine-Induced Relapse
Spencer, S. M., Brown, R. M., Quintero, G. C., Kupchik, Y. M., Thomas, C. A., Reissner, K. J., & Kalivas, P. W. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1204-13.2014 · Cited by 26
Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal
Sánchez-Alavez, M., Benedict, J., Wills, D. N., & Ehlers, C. L. (2019) · SLEEP · doi:10.1093/sleep/zsz020 · Cited by 26
Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol
Lile, J. A., Wesley, M. J., Kelly, T. H., & Hays, L. R. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000187 · Cited by 25
Acquisition of Conditioned Responses to a Novel Alcohol-Paired Cue in Social Drinkers
Mayo, L. M., & de Wit, H. (2016) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2016.77.317 · Cited by 24
Patient-reported sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review
Huhn, A. S., Ellis, J. D., Dunn, K. E., Sholler, D. J., Tabaschek, P., Burns, R., & Strain, E. C. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109508 · Cited by 20
Combined Pharmacotherapies for the Management of Alcoholism: Rationale and Evidence to Date
Lee, M. R., & Leggio, L. (2014) · CNS Drugs · doi:10.1007/s40263-013-0137-z · Cited by 20
Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder
Bedse, G., Centanni, S. W., Winder, D. G., & Patel, S. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14159 · Cited by 19
New dimensions in human laboratory models of addiction
Koob, G. F. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00127.x · Cited by 20
Clinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs
Karoly, H. C., YorkWilliams, S. L., & Hutchison, K. E. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12884 · Cited by 19
Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology
Meredith, L. R., Burnette, E. M., Nieto, S. J., Du, H., Donato, S., Grodin, E. N., Green, R., Magill, M., Baskerville, W., & Ray, L. A. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15143 · Cited by 20
Comparing alcohol cue-reactivity in treatment-seekers versus non-treatment-seekers with alcohol use disorder
Venegas, A., & Ray, L. A. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1635138 · Cited by 20
The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder
Caputo, F., Cibin, M., Loche, A., GIORGIO, R. D., & Zoli, G. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936483 · Cited by 18
The Assessment of Craving in Addiction Research
Ray, L. A., Courtney, K. E., Bacio, G. A., & MacKillop, J. (2013) · Wiley eBooks · doi:10.1002/9781118384404.ch13 · Cited by 17
Alcohol Use Disorders in Geriatrics
Kalapatapu, R. K., Paris, P., & Neugroschl, J. A. (2010) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.40.3.g · Cited by 15
A randomized trial of low-dose gabapentin for post hospitalization relapse prevention in a Thai clinical sample of alcohol dependence
Chompookham, P., Rukngan, W., Nilaban, S., Suwanmajo, S., Yoosom, P., & Kalayasiri, R. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.002 · Cited by 14
Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder
Mason, B. J. (2022) · Alcohol research · doi:10.35946/arcr.v42.1.11 · Cited by 15
Self-citation
A Translational Approach to Novel Medication Development for Protracted Abstinence
Mason, B. J., & Higley, A. E. (2012) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_201 · Cited by 12
Self-citation
The dark side of compulsive eating and food addiction
Zorrilla, E. P., & Koob, G. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816207-1.00006-8 · Cited by 14
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder
Castillo, F., Jones, J. D., Luba, R. R., Mogali, S., Foltin, R. W., Evans, S. M., & Comer, S. D. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173482 · Cited by 10
Addressing negative affect in substance use relapse prevention
Olsson, K. L., Cooper, R. L., Nugent, W. R., & Reid, R. C. (2015) · Journal of Human Behavior in the Social Environment · doi:10.1080/10911359.2015.1058138 · Cited by 10
Characterizing alcohol cue reactive and non-reactive individuals with alcohol use disorder
Kirsch, D. E., Grodin, E. N., & Ray, L. A. (2024) · Addictive Behaviors · doi:10.1016/j.addbeh.2024.108028 · Cited by 9
Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment.
Koob, G. F. (2010) · Europe PMC (PubMed Central) · Cited by 10
Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets
Mason, B. J., Shaham, Y., Weiss, F., & Lê, A. D. (2009) · Alcohol · doi:10.1016/j.alcohol.2009.09.024 · Cited by 9
Self-citation
A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder
Mason, B. J., Estey, D., Roberts, A. J., de Guglielmo, G., George, O., Light, J. M., Stoolmiller, M., Quello, S. B., Skinner, M., Shadan, F. F., et al. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2023.100604 · Cited by 9
Self-citation
Underutilization of Pharmacotherapy for Treatment of Alcohol Use Disorders Part II-Results from a Survey of Practices among North Carolina Mental Health Providers and Brief Review of Efficacy of Available Pharmacotherapies
Penders, T. M., Wuensch, K. L., Davis, J. S., Elnagar, K., & Stanciu, C. N. (2017) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000285 · Cited by 8
A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters
Raskind, M. A., Williams, T., Holmes, H. A., Hart, K. L., Crews, L., Poupore, E. L., Thomas, R. G., Darnell, J., Daniels, C., Goke, K., et al. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14989 · Cited by 7
Effects of a novel GABA ‐B positive allosteric modulator, ASP8062 , on alcohol cue‐elicited craving and naturalistic alcohol consumption in a multisite randomized, double‐blind, placebo‐controlled trial
Schacht, J. P., Ray, L. A., Miranda, R., Falk, D. E., Ryan, M. L., Sakai, J. T., Miotto, K. A., Chun, T. H., Scott, C., Ransom, J. H., et al. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15468 · Cited by 7
Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial
Simpson, T. L., Achtmeyer, C. E., Batten, L., Reoux, J. P., Shofer, J. B., Peskind, E. R., Saxon, A. J., & Raskind, M. A. (2024) · Alcohol and Alcoholism · doi:10.1093/alcalc/agae062 · Cited by 6
Pharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions
Hassell, C., Wilkins, K. M., & Trevisan, L. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0107-z · Cited by 6
Advancements in addressing drug dependence: A review of promising therapeutic strategies and interventions
Guida, C. R., Maia, J. M., Ferreira, L. F. R., Rahdar, A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111070 · Cited by 6
Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder
Gendy, M. N. S., Frey, B. N., Ameringen, M. V., Kuhathasan, N., & MacKillop, J. M. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad031 · Cited by 5
Reductions in World Health Organization risk drinking level are associated with improvements in sleep problems among individuals with alcohol use disorder
Garcia, C. C., Richards, D. K., Tuchman, F. R., Hallgren, K. A., Kranzler, H. R., Aubin, H., O’Malley, S. S., Mann, K. F., Aldridge, A., Hoffman, M., et al. (2024) · Alcohol and Alcoholism · doi:10.1093/alcalc/agae022 · Cited by 4
Gabapentin Reduces Alcohol Intake in Rats by Regulating NF-κB Signaling Pathway Via PPAR γ
Li, J., Xu, K., Ding, H., & Xi, Q. (2021) · Alcohol and Alcoholism · doi:10.1093/alcalc/agab065 · Cited by 4
Treatment of ketamine use disorder with combined gabapentin and topiramate: two case reports
Lee, J., Chopra, N., Costa, T., & George, T. P. (2024) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2024.2353649 · Cited by 4
Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials
Nieto, S. J., & Ray, L. A. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70181 · Cited by 3
Chapter 55. Treatment of Alcohol Use Disorder
Mason, B. J., Ritvo, E. C., & Bonci, A. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as55 · Cited by 3
Self-citation
The Predictive Value of Plasma Bioactive Lipids on Craving in Human Volunteers With Alcohol Use Disorder
Miliano, C., Natividad, L. A., Quello, S. B., Stoolmiller, M., Gregus, A. M., Buczynski, M. W., & Mason, B. J. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100368 · Cited by 3
Self-citation
The alcohol cue‐exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review
Kirsch, D. E., Grodin, E. N., Leggio, L., McKee, S. A., Meredith, L. R., Mereish, E. H., Miranda, R., Nieto, S. J., O’Malley, S. S., Schacht, J. P., et al. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70170 · Cited by 5
Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?
Kleczkowska, P., Smaga, I., Filip, M., & Bujalska‐Zadrożny, M. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9655-z · Cited by 2
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials
McManus, K. R., & Ray, L. A. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2625341 · Cited by 2
A Secondary, Subgroup Analysis of Alcohol Cue‐Exposure Craving in Response to Pharmacological Inhibition of the Growth Hormone Secretagogue Receptor With PF ‐5190457
Tyler, R. E., Abreu, V. E., Farokhnia, M., & Leggio, L. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70366 · Cited by 1

Authors: Mason, B. J., Light, J. M., Williams, L. D., & Drobes, D. J.
Affiliations: Scripps Research Institute (US)
Oregon Research Institute (US)
University of Miami (US)
University of South Florida (US)
Corresponding author: Mason, Barbara J.
ORCID: Light, John M.
Venue: Addiction Biology
Publisher: Wiley
Published: 2008-12-04
Volume: 14
Issue: 1
Pages: 73-83
ISSN: 1355-6215 (ISSN-L)
1369-1600
DOI: 10.1111/j.1369-1600.2008.00133.x
PMC: PMC2758315
OpenAlex: W1924646378
Cited by: 115
References: 63
Citations by year: 2026: 5 · 2025: 2 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 3 · 2020: 12 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 8 · 2014: 6 · 2013: 3 · 2012: 5
FWCI: 4.45
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Addiction Biology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (R01AA012602)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: gabapentin, alcoholism, protracted abstinence, alcohol craving, cue reactivity, relapse prevention, sleep quality, mood
MeSH terms: Gabapentin, Adult, Affect, Alcohol Deterrents, Alcohol Withdrawal Delirium, Alcoholism, Amines, Arousal, Cues, Cyclohexanecarboxylic Acids, Electromyography, Female, gamma-Aminobutyric Acid, Galvanic Skin Response, Heart Rate, Humans, Male, Middle Aged, Motivation, Pain Measurement, Sleep, Temperance, Treatment Outcome, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks